The forgotten lipids: triglycerides, remnant cholesterol, and atherosclerotic cardiovascular disease risk
PB Sandesara, SS Virani, S Fazio… - Endocrine …, 2019 - academic.oup.com
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death
worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of …
worldwide. Low-density lipoprotein cholesterol (LDL-C) is a well-established mediator of …
Exploration and development of PPAR modulators in health and disease: an update of clinical evidence
HS Cheng, WR Tan, ZS Low, C Marvalim… - International journal of …, 2019 - mdpi.com
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the
expression of genes responsible for energy metabolism, cellular development, and …
expression of genes responsible for energy metabolism, cellular development, and …
Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017
M Kinoshita, K Yokote, H Arai, M Iida… - … of atherosclerosis and …, 2018 - jstage.jst.go.jp
Every 5 years, the JAS publishes guidelines for the treatment of dyslipidemia and
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …
atherosclerosis. To date, this society has released four such guidelines. Since 2007, the JAS …
SIRT1 promotes lipid metabolism and mitochondrial biogenesis in adipocytes and coordinates adipogenesis by targeting key enzymatic pathways
The NAD+-dependent deacetylase SIRT1 controls key metabolic functions by deacetylating
target proteins and strategies that promote SIRT1 function such as SIRT1 overexpression or …
target proteins and strategies that promote SIRT1 function such as SIRT1 overexpression or …
Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases
S Yamashita, D Masuda, Y Matsuzawa - Current atherosclerosis reports, 2020 - Springer
Abstract Purpose of Review Reduction of serum low-density lipoprotein cholesterol (LDL-C)
levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) …
levels by statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) …
Oleuropein: A natural antioxidant molecule in the treatment of metabolic syndrome
Olive (Olea europaea Linn., Fam. Oleaceae) is commonly known as Zaytoon in
Mediterranean region. Its fruits and oil are essential components of Mediterranean diets …
Mediterranean region. Its fruits and oil are essential components of Mediterranean diets …
PPAR-targeted therapies in the treatment of non-alcoholic fatty liver disease in diabetic patients
Peroxisome proliferator-activated receptors (PPAR), ligand-activated transcription factors of
the nuclear hormone receptor superfamily, have been identified as key metabolic regulators …
the nuclear hormone receptor superfamily, have been identified as key metabolic regulators …
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-α
This article provides a comprehensive review about the molecular and metabolic actions of
PPAR-α. It describes its structural features, ligand specificity, gene transcription …
PPAR-α. It describes its structural features, ligand specificity, gene transcription …
Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022
T Okamura, K Tsukamoto, H Arai, Y Fujioka… - … of Atherosclerosis and …, 2024 - jstage.jst.go.jp
In Japan, a super-aged society, deaths from atherosclerotic cardiovascular disease
(ASCVD), especially cardiac diseases including coronary artery disease (CAD) such as …
(ASCVD), especially cardiac diseases including coronary artery disease (CAD) such as …
Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia
JC Fruchart - Cardiovascular Diabetology, 2017 - Springer
Despite best evidence-based treatment including statins, residual cardiovascular risk poses
a major challenge for clinicians in the twenty first century. Atherogenic dyslipidaemia, in …
a major challenge for clinicians in the twenty first century. Atherogenic dyslipidaemia, in …